u/kasper_cabrera

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

lead time quoted at checkout is the number to hold them to

biopsy-confirmed is not the same as imaging-suggested

Right, and keeping every date and reference number turns a frustrating process into an auditable one.

modmail first, always, and the thread second

This is the principle the whole site is built on. Publish it or do not enforce it.

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

the ranking formula is published, go and read it

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Mild pushback: a supplier with fewer entries is not worse, it is less sampled. Those are different claims and the table says so.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

New plan year, entirely new criteria, and the denial that had been immovable in the autumn simply did not apply in January.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth les

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

Sent the same compound from QSC and WWB to VendorInvestigate in the same month. Both came back above the claim on the certificate — mine was 97.2% on a stated 97.0%.

The habits from the losing phase are what carry it now. That is not inspirational, it is just what happened.

Not convinced by the ranking-by-vibe approach here. The community number is derived from reports; your feeling is derived from four posts you remember.

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

What does your weigh-in frequency look like at this point?

appetite returns before the scale acknowledges anything

buy small first, test it, then decide

This is the whole method in one sentence.

Agreed — and the corollary is that "no data" and "bad data" have to be written differently. The table separates them for exactly that reason.

The thing that decided it for me was that QST answered a column-and-gradient question in writing without asking why I wanted to know.

Weigh monthly now. Best change I made in the whole run and it cost nothing.

the lowest effective dose is a real target and nobody talks about it

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

Postprandial excursions flattened out first and the fasting number took months to follow. Nobody had told me to expect that order.

the source page log is more useful than the score above it

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range. Two people with identical A1c can have very different distributions.

the lowest effective dose is a real target and nobody talks about it

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

stretching the interval is not the same as reducing the dose

Is that from the source page log or from memory?

the lowest effective dose is a real target and nobody talks about it

Chased the last three kilos with a dose increase and got a fortnight of injection-site soreness and no change in the number.